Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy

Fig. 3

Transcriptional signatures of MDA-MB-231 after BML284/PPP/JK184 treatment. A, B and E Hierarchical clustering of the RNA-seq analysis results shows differentially expressed genes between BML284/PPP/JK184-treated MDA-MB-231 cells and nontreated MDA-MB-231 cells (n = 3). C and D Representative GSEA enrichment plot demonstrating significant downregulation of ECM-receptor interaction pathway-related genes (BML284, FDR = 0.705 and NES = − 1.452, PPP, FDR = 1.0 and NES = − 1.463) and gap junction pathway-related genes (BML284, FDR = 0.12 and NES = − 1.248, PPP, FDR = 1.0 and NES = − 1.225) in BML284/PPP-treated MDA-MB-231 cells versus nontreated MDA-MB-231 cells (WT). F GSEA analysis highlighted the ECM-receptor interaction pathway (FDR = 0.749 and NES = − 1.374), the MAPK pathway (FDR = 0.127 and NES = 1.569), and the TGFβ pathway (FDR = 0.928 and NES = − 1.177) alternations in JK184-treated MDA-MB-231 cells versus nontreated MDA-MB-231 cells (WT)

Back to article page